Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGL-TX-MR Study
2024-513765-40-00Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of empagliflozin in kidney allograft rejection (2 arms), sponsored by University Hospital Odense. Primary endpoint: Kidney allograft cortical and medullary oxygen tension. Started Jan 2025; status: completed.
02
Drugs
empagliflozin
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2024-513765-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513765-40-00.